3/17 Taiwan BIO Weekly
2026-03-17 |
| Taiwan BIO Weekly |
| MegaPro Biomedical plans for Phase III trial of liver cancer MRI contrast agent 12 March, 2026 MegaPro Biomedical (TW: 6827) announced on March 12th that its self-developed liver cancer MRI contrast agent, MPB-1523, is moving forward with multi-country, multi-center Phase III clinical trial planning. The company has submitted a consultation request to the US FDA for the study, and it expects to receive US FDA feedback in Q2 this year, after which it will formally submit the Phase III clinical study application. More... (in Chinese) |
| Libo Pharma starts drug project with Japan university 12 March, 2026 Taipei-based Libo Pharma (TW: 7888) on Tuesday led a delegation to Japan's Fukushima Prefecture to launch a collaborative project with Fukushima Medical University in emergency radiation medicine. The collaboration would be based on LIB-101, Libo Pharma's core investigational drug, which is under development, with the researchers to conduct an investigator-initiated trial (IIT) to study its application in medical management following major radiation accidents. More... |
| Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit Press release 11 March, 2026 Locus Cell Co., Ltd., (TW: 6891) a Taiwan-based cell and gene therapy (CGT) Contract Development and Manufacturing Organization (CDMO), and Charles River Laboratories, a global contract research organization (CRO) providing drug development support and biologics testing solutions, have signed a Memorandum of Understanding (MoU) during the APAC Biomanufacturing Leadership Summit 2026 in Singapore. More... |
| Vaxcellbio inks Asia pet health pact with Taiwan's Reber Genetics 11 March, 2026 [South Korea's] Vaxcellbio said Wednesday that it had signed a master partnership agreement, a broad framework that sets the terms for future technology transfer, supply and export deals, with Reber Genetics (TW: 6479), a Taiwanese developer and distributor of animal vaccines, to expand its pet healthcare business in Asia. More... |
| StemCyte International expands regenerative medicine in Asia-Pacific with Malaysian MOU 10 March, 2026 StemCyte International (TW: 4178) announced March 9th that following its operations in Taiwan and the US, it is officially expanding its regenerative medicine presence across the Asia-Pacific region. The company signed a strategic cooperation memorandum of understanding (MOU) with a leading Malaysian biotech firm to implement its public inventory protection program in Southeast Asia. The program centers on cross-border protection, international supply, and local services, connecting regional partners with clinical demand to establish a scalable and replicable international collaboration framework. More... (in Chinese) |
| Elixiron Immunotherapeutics partners with Japanese firm to develop stem cell therapy 10 March, 2026 Innovative drug developer Elixiron Immunotherapeutics (TW: 7871) has announced a strategic cooperation memorandum of understanding (MOU) with CUORiPS, a leading Japanese company in induced pluripotent stem cell (iPSC) regenerative medicine. The partnership aims to optimize the post-allogeneic transplant microenvironment through precise immune modulation, with the goal of reducing rejection risk and improving therapy safety. More... (in Chinese) |
| Anya Biopham launches Phase I clinical trial for new oral GLP-1 tablet 9 March, 2026 Anya Biopham (TW: 7776) announced that its second oral GLP-1 drug candidate, ANY004, has recently received approval from Australia's Human Research Ethics Committee (HREC) to begin a Phase I clinical trial. The study will primarily compare ANY004 with Eli Lilly's subcutaneous injection product Mounjaro. More... (in Chinese) |
| Steminent Biotherapeutics launches US Phase II clinical trial for stem cell new drug 9 March, 2026 Stem cell therapy company Steminent Biotherapeutics (TW: 7729) announced on March 9th the launch of a US Phase II clinical trial for its stem cell drug Stemchymal for the treatment of spinocerebellar ataxia (SCA), also known as cerebellar atrophy. The company is also advancing regulatory approvals in Taiwan and Japan, along with preparations for commercial-scale manufacturing. Steminent Biotherapeutics plans to work with domestic and international clinical and industry partners to establish a global benchmark for Taiwan-developed cell therapies targeting rare diseases. More... (in Chinese) |
| BioGend Therapeutics' SoufCut receives Taiwan approval, boosting its regenerative medicine expansion 9 March, 2026 BioGend Therapeutics (TW: 6733) announced that its "SoufCut Soft Tissue Processing System" has received a Class II medical device approval from Taiwan's FDA. The system can process autologous fat tissue to extract stromal vascular fraction (SVF) containing various regenerative cells, potentially enabling applications in soft tissue repair and other regenerative medicine therapies, adding new momentum to the company's regenerative medicine portfolio. Additionally, the company is advancing the Phase III clinical trial of its core product, Osteoinductive Factor (OIF), aiming to move the product toward commercialization. OIF is primarily intended for fracture repair and bone regeneration and is considered one of the company's most promising growth drivers. More... (in Chinese) |
| Heron Neutron Medical teams up with PELL Bio-Med Technology for AB-BNCT and immunotherapy 9 March, 2026 Heron Neutron Medical (TW: 7799) and PELL Bio-Med Technology (TW: 6949) have signed a strategic alliance memorandum of understanding to jointly develop precision therapies combining Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) with CAR-T immunotherapy. The collaboration will integrate each company's strengths to advance preclinical research, translational validation, and subsequent clinical development. In this partnership, the two companies leverage their respective expertise: Heron Neutron Medical focuses on AB-BNCT medical devices and therapeutic drug development, with key technologies for clinical and treatment planning targeting solid tumors. PELL Bio-Med Technology, meanwhile, has developed Taiwan's first homegrown CAR-T product with local manufacturing capabilities, specializing in research and translational development of cellular immunotherapies. More... (in Chinese) |
| Taiwan aims for NT$180 billion pharma output with new initiatives 6 March, 2026 The government will launch initiatives to boost the domestic drug supply chain and expand collaborative R&D with international partners to help Taiwan's pharmaceutical output reach NT$180 billion (US$5.7 billion). President Lai Ching-te said the government will spend NT$24 billion on a four-year program to support the sector. The initiative aims to strengthen the production of pharmaceutical ingredients, drug storage, and supply management to ensure Taiwan's healthcare system remains stable amid geopolitical changes, per CNA. More... |
| TCM Biotech eyes Taiwan main board listing in April 6 March, 2026 The Taiwan stock market will gain a new player as TCM Biotech International Corp. prepares to list on the main board in April. The company is currently traded on Taiwan's over-the-counter market, closing at NT$237.5 (US$7.5) on Friday. It plans an underwriting price of NT$132 per share for the main board listing, according to CTEE and Anue. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |